These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
331 related items for PubMed ID: 17186528
1. Cumulative cost pattern comparison of prostate cancer treatments. Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR. Cancer; 2007 Feb 01; 109(3):518-27. PubMed ID: 17186528 [Abstract] [Full Text] [Related]
2. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy. Poon I, Pintilie M, Potvin M, McGowan T. Can J Urol; 2004 Feb 01; 11(1):2125-32. PubMed ID: 15003151 [Abstract] [Full Text] [Related]
3. The economic burden of prostate cancer, California, 1998. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. Cancer; 2002 Jun 01; 94(11):2906-13. PubMed ID: 12115378 [Abstract] [Full Text] [Related]
4. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Crawford ED, Black L, Eaddy M, Kruep EJ. Prostate Cancer Prostatic Dis; 2010 Jun 01; 13(2):162-7. PubMed ID: 20125121 [Abstract] [Full Text] [Related]
5. Prostate cancer--prevalence-based healthcare costs. Norlund A, Alvegård T, Lithman T, Merlo J, Noreen D. Scand J Urol Nephrol; 2003 Jun 01; 37(5):371-5. PubMed ID: 14594683 [Abstract] [Full Text] [Related]
6. Adenocarcinoma of the prostate: an expensive way to die. Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T. Prostate Cancer Prostatic Dis; 2002 Jun 01; 5(2):164-6. PubMed ID: 12497008 [Abstract] [Full Text] [Related]
7. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population. Sennfält K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E. Scand J Urol Nephrol; 2003 Jun 01; 37(3):226-31. PubMed ID: 12775282 [Abstract] [Full Text] [Related]
8. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. CMAJ; 2000 Apr 04; 162(7):977-83. PubMed ID: 10763395 [Abstract] [Full Text] [Related]
9. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. J Urol; 2007 Oct 04; 178(4 Pt 1):1423-8. PubMed ID: 17706711 [Abstract] [Full Text] [Related]
10. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR, CaPSURE Investigators. J Urol; 2007 Aug 04; 178(2):529-34; discussion 534. PubMed ID: 17570425 [Abstract] [Full Text] [Related]
11. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Brandeis J, Pashos CL, Henning JM, Litwin MS. Cancer; 2000 Oct 15; 89(8):1792-9. PubMed ID: 11042575 [Abstract] [Full Text] [Related]
12. Predictors of patient reported outcomes and cost of care in younger men with newly diagnosed prostate cancer. Jayadevappa R, Chhatre S, Wein AJ, Malkowicz SB. Prostate; 2009 Jul 01; 69(10):1067-76. PubMed ID: 19343738 [Abstract] [Full Text] [Related]
13. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor. Sadetsky N, Lubeck DP, Pasta DJ, Latini DM, DuChane J, Carroll PR. BJU Int; 2008 Mar 01; 101(6):691-7. PubMed ID: 18291018 [Abstract] [Full Text] [Related]
14. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database. Sadetsky N, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. Prostate Cancer Prostatic Dis; 2008 Mar 01; 11(3):280-7. PubMed ID: 17893700 [Abstract] [Full Text] [Related]
15. Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer. Jayadevappa R, Bloom BS, Chhatre S, Fomberstein KM, Wein AJ, Malkowicz SB. J Urol; 2005 Sep 01; 174(3):1059-64; discussion 1064. PubMed ID: 16094058 [Abstract] [Full Text] [Related]
16. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA. Urology; 1997 Nov 01; 50(5):747-53. PubMed ID: 9372886 [Abstract] [Full Text] [Related]
17. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. Fourcade RO, Benedict A, Black LK, Stokes ME, Alcaraz A, Castro R. BJU Int; 2010 Jan 01; 105(1):49-56. PubMed ID: 20132102 [Abstract] [Full Text] [Related]
18. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Cancer; 2006 May 01; 106(9):1875-82. PubMed ID: 16572409 [Abstract] [Full Text] [Related]
19. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Alexandrescu DT. Dermatol Online J; 2009 Nov 15; 15(11):1. PubMed ID: 19951637 [Abstract] [Full Text] [Related]
20. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults. Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L. Am J Geriatr Pharmacother; 2008 Aug 15; 6(3):138-46. PubMed ID: 18775388 [Abstract] [Full Text] [Related] Page: [Next] [New Search]